Pharmaceutical Technology1 天
NUC-7738 by NuCana for Lung Adenocarcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical ...
Pharmaceutical Technology1 天
Erdafitinib by Johnson & Johnson for Lung Adenocarcinoma: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase I for Lung Adenocarcinoma.
ahmedabadmirror14 天
Why are non-smokers getting lung cancer?
Lung cancer, long known to affect smokers, is seeing a significant rise in people who do not smoke, said doctors, raising ...
Cure Today4 天
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...
Study unravels the earliest cellular genesis of lung adenocarcinoma
uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung ...
FDA approves Bristol Myers’ Opdivo Qvantig
The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...